Relation Between BRAF<sup>V600E</sup> Mutation and Thyroglobulin or Clinicopathologic Characteristics of Papillary Thyroid Carcinoma_CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Authors：

 ZHANGWei , WANGNan-peng , GAOQing-jun , ZHOUYan , DUANHai-song , ZHANGWei ,  ZHAODai-wei

Department of Thyroid Surgery, Affiliated Hospital of Guiyang Medical College, Guiyang 550004, Guizhou Province, China;

Corresponding?author：

ZHAODai-wei, Email: zhaodw@hotmail.com

Keywords：

Papillary thyroid carcinoma; BRAFV600E mutation; Thyroglobulin

DOI：

10.7507/1007-9424.20150054

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To discuss the correlation of BRAF^V600E mutation with clinicopathologic characteristics or thyroglobulin (Tg) in papillary thyroid carcinoma (PTC) and its clinical significance. Methods The BRAF^V600E mutations of 55 patients with PTC were detected by nested PCR. The relations between BRAF^V600E mutation and the clinicopathologic characteristics were analyzed. Results ①The BRAF^V600E mutations happened in 29 patients with PTC, the mutation rate was 52.7% (29/55).②The BRAF^V600E mutation rate was related with extracapsular spread, multiple lesions, regional lymph node metastasis or average Tg value > 1.0μg/L during 2 years after standardized treatment (P value was 0.01, 0.02, 0.02, 0.03, respectively), but which not related with the gender, age, tumor diameter, or TNM stage (P > 0.05). Conclusion The BRAF^V600E mutation in PTC might lead to increased tumor aggressiveness and it might be related with increased Tg value after standardized treatment.

Citation： ZHANGWei, WANGNan-peng, GAOQing-jun, ZHOUYan, DUANHai-song, ZHANGWei, ZHAODai-wei. Relation Between BRAF^V600E Mutation and Thyroglobulin or Clinicopathologic Characteristics of Papillary Thyroid Carcinoma. CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 2015, 22(2): 200-203. doi: 10.7507/1007-9424.20150054 Copy

1.	?鄭瑩, 吳春曉, 金凡, 等.上海市區1973至2005年癌癥的發病趨勢.診斷學理論與實踐, 2009, 8(1): 25-32.
2.	高明, 滕衛平, 劉永峰, 等.甲狀腺結節和分化型甲狀腺癌診治指南.中國腫瘤臨床, 2012, 39(17): 1249-1272.
3.	Ikawa S, Fukui M, Ueyama Y, et al. B-raf, a new member of the raf family, is activated by DNA rearrangement. Mol Cell Biol, 1988, 8(6): 2651-2654.
4.	Xing M, Westra WH, Tufano RP, et al. BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer. J Clin Endocrinol Metab, 2005, 90(12): 6373-6379.
5.	Xing M, Tufano RP, Tufaro AP, et al. Detection of BRAF mutation on fine needle aspiration biopsy specimens: a new diagnostic tool for papillary thyroid cancer. J Clin Endocrinol Metab, 2004, 89(6): 2867-2872.
6.	Sapio MR, Posca D, Troncone G, et al. Detection of BRAF mutation in thyroid papillary carcinomas by mutant allele-specific PCR amplification (MASA). Eur J Endocrinol, 2006, 154(2): 341-348.
7.	Frattini M, Ferrario C, Bressan P, et al. Alternative mutations of BRAF, RET and NTRK1 are associated with similar but distinct gene expression patterns in papillary thyroid cancer. Oncogene, 2004, 23(44): 7436-7440.
8.	Namba H, Nakashima M, Hayashi T, et al. Clinical implication of hot spot BRAF mutation, V599E, in papillary thyroid cancers. J Clin Endocrinol Metab, 2003, 88(9): 4393-4397.
9.	Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature, 2002, 417(6892): 949-954.
10.	Xing M, Clark D, Guan H, et al. BRAF mutation testing of thyroid fine-needle aspiration biopsy specimens for preoperative risk stratification in papillary thyroid cancer. J Clin Oncol, 2009, 27(18): 2977-2982.
11.	Henderson YC, Shellenberger TD, Williams MD, et al. High rate of BRAF and RET/PTC dual mutations associated with recurrent papillary thyroid carcinoma. Clin Cancer Res, 2009, 15(2): 485-491.
12.	牛衛, 羅月球, 陳麗榮.甲狀腺乳頭狀癌BRAF基因突變及表達的臨床意義研究.實用腫瘤雜志, 2008, 23(6): 519-523.
13.	Puxeddu E, Moretti S. Clinical prognosis in BRAF-mutated PTC. Arq Bras Endocrinol Metabol, 2007, 51(5): 736-747.
14.	Elisei R, Ugolini C, Viola D, et al. BRAF(V600E) mutation and outcome of patients with papillary thyroid carcinoma: a 15-year median follow-up study. J Clin Endocrinol Metab, 2008, 93(10): 3943-3949.
15.	Giovanella L, Ceriani L, Ghelfo A, et al. Thyroglobulin assay 4 weeks after thyroidectomy predicts outcome in low-risk papillary thyroid carcinoma. Clin Chem Lab Med, 2005, 43(8): 843-847.
16.	羅家倫, 徐慧琴, 趙學峰, 等.甲狀腺球蛋白及抗甲狀腺球蛋白抗體聯合頸部超聲在分化型甲狀腺癌復發或轉移灶診斷中的價值.中華臨床醫師雜志:電子版, 2012, 6(3): 580-583.
17.	Boi F, Baghino G, Atzeni F, et al. The diagnostic value for differentiated thyroid carcinoma metastases of thyroglobulin (Tg) measurement in washout fluid from fine-needle aspiration biopsy of neck lymph nodes is maintained in the presence of circulating anti-Tg antibodies. J Clin Endocrinol Metab, 2006, 91(4): 1364-1369.
18.	Riesco-Eizaguirre G, Rodríguez I, De la Vieja A, et al. The BRAFV600E oncogene induces transforming growth factor beta secretion leading to sodium iodide symporter repression and increased malignancy in thyroid cancer. Cancer Res, 2009, 69(21): 8317-8325.

1. ?鄭瑩, 吳春曉, 金凡, 等.上海市區1973至2005年癌癥的發病趨勢.診斷學理論與實踐, 2009, 8(1): 25-32.
2. 高明, 滕衛平, 劉永峰, 等.甲狀腺結節和分化型甲狀腺癌診治指南.中國腫瘤臨床, 2012, 39(17): 1249-1272.
3. Ikawa S, Fukui M, Ueyama Y, et al. B-raf, a new member of the raf family, is activated by DNA rearrangement. Mol Cell Biol, 1988, 8(6): 2651-2654.
4. Xing M, Westra WH, Tufano RP, et al. BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer. J Clin Endocrinol Metab, 2005, 90(12): 6373-6379.
5. Xing M, Tufano RP, Tufaro AP, et al. Detection of BRAF mutation on fine needle aspiration biopsy specimens: a new diagnostic tool for papillary thyroid cancer. J Clin Endocrinol Metab, 2004, 89(6): 2867-2872.
6. Sapio MR, Posca D, Troncone G, et al. Detection of BRAF mutation in thyroid papillary carcinomas by mutant allele-specific PCR amplification (MASA). Eur J Endocrinol, 2006, 154(2): 341-348.
7. Frattini M, Ferrario C, Bressan P, et al. Alternative mutations of BRAF, RET and NTRK1 are associated with similar but distinct gene expression patterns in papillary thyroid cancer. Oncogene, 2004, 23(44): 7436-7440.
8. Namba H, Nakashima M, Hayashi T, et al. Clinical implication of hot spot BRAF mutation, V599E, in papillary thyroid cancers. J Clin Endocrinol Metab, 2003, 88(9): 4393-4397.
9. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature, 2002, 417(6892): 949-954.
10. Xing M, Clark D, Guan H, et al. BRAF mutation testing of thyroid fine-needle aspiration biopsy specimens for preoperative risk stratification in papillary thyroid cancer. J Clin Oncol, 2009, 27(18): 2977-2982.
11. Henderson YC, Shellenberger TD, Williams MD, et al. High rate of BRAF and RET/PTC dual mutations associated with recurrent papillary thyroid carcinoma. Clin Cancer Res, 2009, 15(2): 485-491.
12. 牛衛, 羅月球, 陳麗榮.甲狀腺乳頭狀癌BRAF基因突變及表達的臨床意義研究.實用腫瘤雜志, 2008, 23(6): 519-523.
13. Puxeddu E, Moretti S. Clinical prognosis in BRAF-mutated PTC. Arq Bras Endocrinol Metabol, 2007, 51(5): 736-747.
14. Elisei R, Ugolini C, Viola D, et al. BRAF(V600E) mutation and outcome of patients with papillary thyroid carcinoma: a 15-year median follow-up study. J Clin Endocrinol Metab, 2008, 93(10): 3943-3949.
15. Giovanella L, Ceriani L, Ghelfo A, et al. Thyroglobulin assay 4 weeks after thyroidectomy predicts outcome in low-risk papillary thyroid carcinoma. Clin Chem Lab Med, 2005, 43(8): 843-847.
16. 羅家倫, 徐慧琴, 趙學峰, 等.甲狀腺球蛋白及抗甲狀腺球蛋白抗體聯合頸部超聲在分化型甲狀腺癌復發或轉移灶診斷中的價值.中華臨床醫師雜志:電子版, 2012, 6(3): 580-583.
17. Boi F, Baghino G, Atzeni F, et al. The diagnostic value for differentiated thyroid carcinoma metastases of thyroglobulin (Tg) measurement in washout fluid from fine-needle aspiration biopsy of neck lymph nodes is maintained in the presence of circulating anti-Tg antibodies. J Clin Endocrinol Metab, 2006, 91(4): 1364-1369.
18. Riesco-Eizaguirre G, Rodríguez I, De la Vieja A, et al. The BRAFV600E oncogene induces transforming growth factor beta secretion leading to sodium iodide symporter repression and increased malignancy in thyroid cancer. Cancer Res, 2009, 69(21): 8317-8325.

CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Relation Between BRAF^V600E Mutation and Thyroglobulin or Clinicopathologic Characteristics of Papillary Thyroid Carcinoma

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content

CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Relation Between BRAFV600E Mutation and Thyroglobulin or Clinicopathologic Characteristics of Papillary Thyroid Carcinoma

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content

Relation Between BRAF^V600E Mutation and Thyroglobulin or Clinicopathologic Characteristics of Papillary Thyroid Carcinoma